B. Riley Financial Reaffirms “Neutral” Rating for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “neutral” rating reissued by analysts at B. Riley Financial in a note issued to investors on Wednesday, Marketbeat reports. They currently have a $14.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $28.00. B. Riley Financial’s price objective would indicate a potential upside of 3.09% from the company’s previous close.

Several other equities research analysts have also recently issued reports on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Theravance Biopharma in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. BTIG Research dropped their price objective on shares of Theravance Biopharma from $40.00 to $21.00 and set a “buy” rating for the company in a report on Tuesday. HC Wainwright raised their price objective on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research report on Monday. Finally, Oppenheimer initiated coverage on Theravance Biopharma in a report on Wednesday, December 3rd. They issued an “outperform” rating and a $27.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.60.

Theravance Biopharma Trading Down 0.6%

Shares of TBPH opened at $13.58 on Wednesday. The business’s 50 day moving average is $19.06 and its 200 day moving average is $16.83. Theravance Biopharma has a 12-month low of $7.90 and a 12-month high of $21.03. The company has a market capitalization of $688.10 million, a PE ratio of 23.82 and a beta of 0.17.

Institutional Trading of Theravance Biopharma

Several hedge funds have recently made changes to their positions in TBPH. Quarry LP bought a new position in shares of Theravance Biopharma in the 3rd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,411 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 515 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 781 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its position in shares of Theravance Biopharma by 20,269.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 4,662 shares during the last quarter. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.